Web Exclusive

These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.
AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.

Results 1 - 4 of 4

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code